Latest AAHRPP Accreditation Reflects Inroads in Asia
The Association for the Accreditation of Human Research Protection Programs (AAHRPP) announced that it has accredited seven more organizations. Three of the newly accredited organizations are in Asia.
The Association for the Accreditation of Human Research Protection Programs (AAHRPP) announced that it has accredited seven more organizations. Three of the newly accredited organizations are in Asia.
The newly accredited organizations are:
• Loyola University Chicago, Health Sciences Division, Maywood, Illinois
• Peking University, Beijing, China
• Taipei Medical University - Shuang Ho Hospital, New Taipei City, Taiwan
• Texas A & M University, College Station, Texas
• University of California, Davis, Davis, California
• University of Miami, Coral Gables, Florida
• Wan Fang Municipal Hospital, Taipei Medical University, Taipei, Taiwan
To earn AAHRPP accreditation, organizations must demonstrate that they have built extensive safeguards into every level of their research operation and that they adhere to high standards for research. To date, AAHRPP has accredited more than 210 organizations in 46 states, Canada, China, India, Mexico, Republic of Korea, Saudi Arabia, Singapore, Taiwan, and Thailand.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
